---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-075736"
form_type: "8-K/A"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:19:00.652581+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics files audited FY2022 financials with net loss of $37.7M; pro forma cash from $164.5M financing

## Summary
- Net loss of $37.7M for year ended Dec 31, 2022 vs $24.7M in 2021; R&D spend rose 51% to $31.0M.
- Cash and equivalents of $75.5M at Dec 31, 2022; $164.5M PIPE closed concurrently with merger on Feb 23, 2023.
- Pro forma financials reflect reverse recapitalization with Imara Inc.; Enliven is accounting acquirer.
- Accumulated deficit of $82.9M; company expects current cash to fund ops for at least 12 months.
- Audited balance sheet shows total assets of $83.3M and total liabilities of $10.4M at Dec 31, 2022.

## SEC filing metadata
- accession: 0001193125-23-075736
- form_type: 8-K/A
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312523075736/0001193125-23-075736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312523075736/d415677d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-075736
- JSON: https://secwatch.observer/filing/0001193125-23-075736.json
- Plain text: https://secwatch.observer/filing/0001193125-23-075736.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.